Gossamer Bio, Inc. (NASDAQ:GOSS - Free Report) - Investment analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Gossamer Bio in a research note issued to investors on Thursday, January 30th. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings per share of $0.59 for the year. HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Gossamer Bio's current full-year earnings is ($0.28) per share.
Gossamer Bio (NASDAQ:GOSS - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.04. The firm had revenue of $9.48 million during the quarter, compared to analysts' expectations of $4.52 million.
Gossamer Bio Stock Performance
Shares of GOSS traded down $0.01 during trading hours on Friday, hitting $1.02. The company's stock had a trading volume of 858,860 shares, compared to its average volume of 954,081. The company has a market cap of $231.13 million, a price-to-earnings ratio of -3.19 and a beta of 1.81. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74. The business has a 50 day simple moving average of $0.87 and a two-hundred day simple moving average of $0.90. Gossamer Bio has a 52-week low of $0.50 and a 52-week high of $1.60.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of GOSS. Marshall Wace LLP boosted its holdings in shares of Gossamer Bio by 170.8% in the second quarter. Marshall Wace LLP now owns 3,335,511 shares of the company's stock worth $3,002,000 after acquiring an additional 2,103,766 shares during the period. Renaissance Technologies LLC boosted its stake in Gossamer Bio by 204.7% in the 2nd quarter. Renaissance Technologies LLC now owns 2,046,600 shares of the company's stock worth $1,844,000 after purchasing an additional 1,375,000 shares during the period. Jacobs Levy Equity Management Inc. grew its holdings in Gossamer Bio by 30.7% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,887,512 shares of the company's stock valued at $1,862,000 after buying an additional 442,895 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in Gossamer Bio by 67.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 310,213 shares of the company's stock valued at $279,000 after buying an additional 124,913 shares in the last quarter. Finally, Algert Global LLC purchased a new stake in shares of Gossamer Bio in the second quarter worth about $75,000. 81.23% of the stock is currently owned by hedge funds and other institutional investors.
About Gossamer Bio
(
Get Free Report)
Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.
See Also
Before you consider Gossamer Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gossamer Bio wasn't on the list.
While Gossamer Bio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
